Pharma Leader Series: Top 50 Generic
Drug Manufacturers 2013-2023
and filling and finishing injectable products. It supplies its goods to hospitals, clinics, home
healthcare providers and long-term care facilities.
Figure 4.7 Hospira: Business Segment Revenue Breakdown by Region ($m), 2012
Revenues ($m) 2012
3000
2500
2000
1500
1000
500
0
Specialty Injectables
Medication management
Segment
Americas
EMEA
Other pharma
APAC
Source: Company reports; visiongain 2013
4.5.5 Orchid Acquisition Signalling an Indian Strategy for Hospira?
In August 2012, Hospira acquired Orchid Chemicals & Pharmaceuticals’ penem and penicillin API
business for just over $202m in cash. Orchid is an Indian company, and Hospira’s involvement with
Orchid since 2010 is an indication the company will be expanding its operations in India in the near
future. Hospira also acquired Javelin Pharmaceuticals in 2010, with the intent of using synergies
between its leading Precedex product and Javelin’s post-operative pain management candidate
drug Dyloject. Hospira also entered into collaborative agreements with DURECT Corporation and
Kiadis Pharma. Hospira has also established a licensing deal for a ChemGenex oncology product
candidate, and has acquired facilities and product rights in the biosimilars field from PLIVA
Hrvatska, Human Genome Sciences and Celltrion. It has a joint venture (Zydus Hospira Oncology)
with Cadila Healthcare.
4.5.6 Growth Forecast for Hospira Generics, 2013-2023
Visiongain believes Hospira’s generics business will achieve a 2012-2017 CAGR of 3% and reach
sales of $2550m in that year. The relatively slow growth will result from increasing competition in
the injectables segment, which has been targeted by multiple companies seeking opportunities in
www.visiongain.com
Page 77
Pharma Leader Series: Top 50 Generic
Drug Manufacturers 2013-2023
speciality generic pharma sectors. However, opportunities in new markets including India will see
Hospira’s generics business (though the company’s other businesses may perform more strongly),
reaching revenues of $3437m by the end of the forecast period, with a five-year CAGR of 5%. See
Table 4.9, Table 4.10 and Figure 4.8.
Table 4.9 Hospira: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Revenues ($m )
2012
2013
2014
2015
2016
2017
2202
2350
2412
2450
2490
2550
7
3
2
2
2
AGR (%)
3
CAGR (%, 2012-2017)
Source: visiongain 2013
Table 4.10 Hospira: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
2018
2019
2020
2021
2022
2023
Revenues ($m )
2660
2790
2932
3100
3260
3437
AGR (%)
4
5
5
6
5
5
CAGR (%, 2018-2023)
5
Source: visiongain 2013
Figure 4.8 Hospira: Generic Revenues ($m), 2012-2023
4000
3500
Revenues ($m)
3000
2500
2000
1500
1000
500
0
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Year
Source: visiongain 2013
www.visiongain.com
Page 78